iPSC-based research in ALS precision medicine

Clinical trials in amyotrophic lateral sclerosis (ALS) are challenged by the lack of pre-clinical models and biomarkers of disease onset and progression. In this issue, Morimoto et al. use induced pluripotent stem cell (iPSC)-derived motor neurons from patients with ALS to study therapeutic mechanisms of ropinirole in a clinical trial and identify treatment responders.

Automated summary

The lack of pre-clinical models and biomarkers has made clinical trials in amyotrophic lateral sclerosis (ALS) challenging. Morimoto et al. used induced pluripotent stem cell (iPSC)-derived motor neurons from ALS patients to study the therapeutic mechanisms of ropinirole in a clinical trial and identify responders.